Bellicum Pharmaceuticals, Inc. (BLCM) Stock Price Down 7.1%

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) shares dropped 7.1% during mid-day trading on Wednesday . The company traded as low as $11.56 and last traded at $11.79. Approximately 1,191,040 shares changed hands during mid-day trading, an increase of 40% from the average daily volume of 850,539 shares. The stock had previously closed at $12.69.

BLCM has been the topic of a number of recent research reports. Jefferies Group LLC restated a “buy” rating and issued a $16.00 price target (down from $18.00) on shares of Bellicum Pharmaceuticals in a research report on Thursday, August 10th. Raymond James Financial, Inc. set a $18.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Cantor Fitzgerald set a $32.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, June 24th. Ladenburg Thalmann Financial Services set a $31.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, June 24th. Finally, Wells Fargo & Company restated an “outperform” rating and issued a $31.00 price target on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Bellicum Pharmaceuticals currently has an average rating of “Hold” and an average target price of $26.20.

The firm’s market cap is $391.73 million. The stock has a 50-day moving average price of $9.61 and a 200-day moving average price of $11.71.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same quarter last year, the company posted ($0.61) earnings per share. Analysts anticipate that Bellicum Pharmaceuticals, Inc. will post ($3.02) earnings per share for the current year.

In related news, insider David M. Spencer sold 10,000 shares of the company’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $11.54, for a total transaction of $115,400.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Ken Moseley sold 13,823 shares of the company’s stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $12.26, for a total transaction of $169,469.98. Following the transaction, the vice president now owns 14,314 shares in the company, valued at approximately $175,489.64. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,260 shares of company stock worth $290,048. 23.30% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System lifted its position in Bellicum Pharmaceuticals by 16.7% during the 2nd quarter. California State Teachers Retirement System now owns 48,146 shares of the biopharmaceutical company’s stock worth $562,000 after buying an additional 6,900 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Bellicum Pharmaceuticals by 26.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,319 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 4,684 shares in the last quarter. State Street Corp lifted its position in Bellicum Pharmaceuticals by 16.6% during the 2nd quarter. State Street Corp now owns 416,966 shares of the biopharmaceutical company’s stock worth $4,872,000 after buying an additional 59,321 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Bellicum Pharmaceuticals by 223.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 138,000 shares of the biopharmaceutical company’s stock worth $1,612,000 after buying an additional 95,336 shares in the last quarter. Finally, HighTower Advisors LLC acquired a new position in Bellicum Pharmaceuticals during the 2nd quarter worth about $448,000. Institutional investors and hedge funds own 55.73% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.chaffeybreeze.com/2017/09/20/bellicum-pharmaceuticals-inc-blcm-stock-price-down-7-1.html.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply